Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101597070 Publication Model: eCollection Cited Medium: Internet ISSN: 2213-1582 (Electronic) Linking ISSN: 22131582 NLM ISO Abbreviation: Neuroimage Clin Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Amsterdam] : Elsevier
    • Subject Terms:
      Self Report*; Breast Neoplasms/*diagnostic imaging ; Cognition/*physiology ; Estrogen Antagonists/*administration & dosage ; Hippocampus/*diagnostic imaging ; Nerve Net/*diagnostic imaging; Adult ; Breast Neoplasms/blood ; Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant/adverse effects ; Cognition/drug effects ; Cognitive Dysfunction/blood ; Cognitive Dysfunction/chemically induced ; Cognitive Dysfunction/diagnostic imaging ; Cross-Sectional Studies ; Estrogen Antagonists/adverse effects ; Female ; Hippocampus/drug effects ; Humans ; Inflammation Mediators/blood ; Magnetic Resonance Imaging/methods ; Nerve Net/drug effects ; Photic Stimulation/methods ; Tamoxifen/administration & dosage ; Tamoxifen/adverse effects
    • Abstract:
      Nearly three out of four survivors experience Cancer-Related Cognitive Impairment (CRCI) for months or years following treatment. Both clinical and animal studies point to the hippocampus as a likely brain region affected in CRCI, however no previous study has investigated the functional connectivity of the hippocampus in CRCI. We compared hippocampal connectivity in cancer survivors and healthy controls and tested the relationship between functional connectivity differences and measures of objective and subjective cognition. Exploratory analysis of inflammatory markers was conducted in a small subset of participants as well. FMRI data were acquired during a memory task from 16 breast cancer survivors and 17 controls. The NIH Toolbox was used to assess cognitive performance and Neuro-QoL was used to measure self-reported cognitive concerns. Whole-brain group-level comparisons identified clusters with different connectivity to the hippocampus in survivors versus controls during task. Average connectivity was extracted from clusters of significant difference between the groups and correlated with cognitive performance and subjective report. Survivors performed worse on a test of episodic memory and reported greater cognitive concern than controls. Exploratory analysis found higher IL6 in cancer survivors compared to controls. Cancer survivors demonstrated higher connectivity of hippocampus with left cuneus, left lingual, left precuneus, and right middle prefrontal gyrus compared with controls. In survivors, higher task-related hippocampal-cortical connectivity was related to worse subjective measures of cognitive concern. Of the four significant clusters, higher connectivity of the precuneus with hippocampus was significantly associated with worse cognitive concern in survivors. The observed greater hippocampal-cortical connectivity in survivors compared to controls is the first reported fMRI biomarker of subjective concern, and may represent a compensatory response to cancer and its treatments. This compensation could explain, in part, the subjective feelings of cognitive impairment that were reported by survivors.
    • References:
      Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11600-5. (PMID: 23798392)
      Magn Reson Med. 1995 May;33(5):636-47. (PMID: 7596267)
      Neurobiol Aging. 2014 Sep;35 Suppl 2:S11-9. (PMID: 24913897)
      Behav Brain Res. 2010 Mar 5;207(2):265-72. (PMID: 19840821)
      Psychooncology. 2007 Aug;16(8):772-7. (PMID: 17152119)
      Ann Oncol. 2015 Jul;26(7):1446-51. (PMID: 25922060)
      Iran Biomed J. 2009 Oct;13(4):237-43. (PMID: 19946350)
      Cancer. 2007 Jan 1;109(1):146-56. (PMID: 17131349)
      Hippocampus. 2005;15(8):997-1005. (PMID: 16281291)
      Exp Brain Res. 2013 Feb;224(3):393-410. (PMID: 23178904)
      Chin Med J (Engl). 2012 Feb;125(4):604-10. (PMID: 22490482)
      Sensors (Basel). 2013 Mar 06;13(3):3169-203. (PMID: 23467031)
      J Neuroimmunol. 2018 Jan 15;314:17-23. (PMID: 29128118)
      Clin Cancer Res. 2009 Nov 1;15(21):6665-73. (PMID: 19843664)
      Hum Brain Mapp. 2011 Aug;32(8):1206-19. (PMID: 20669165)
      Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
      Neuroimage. 2002 Nov;17(3):1394-402. (PMID: 12414279)
      Neuron. 2012 Dec 20;76(6):1057-70. (PMID: 23259943)
      Brain Behav Immun. 2013 Mar;30 Suppl:S109-16. (PMID: 22698992)
      J Int Neuropsychol Soc. 2014 Apr;20(4):391-401. (PMID: 24135221)
      Breast Cancer Res Treat. 2013 Jan;137(1):33-43. (PMID: 23053652)
      J Neurosci. 2007 Feb 28;27(9):2349-56. (PMID: 17329432)
      J Clin Oncol. 2012 Oct 20;30(30):3675-86. (PMID: 23008308)
      Brain Res. 2013 Jan 25;1492:72-91. (PMID: 23142268)
      Support Care Cancer. 2011 Oct;19(10):1647-56. (PMID: 20820813)
      J Clin Oncol. 2010 Oct 10;28(29):4434-40. (PMID: 20837957)
      J Neurosci. 2003 Feb 1;23(3):986-93. (PMID: 12574428)
      Br J Cancer. 2006 Mar 27;94(6):828-34. (PMID: 16523200)
      Neurology. 2013 Mar 12;80(11 Suppl 3):S54-64. (PMID: 23479546)
      Brain Imaging Behav. 2013 Dec;7(4):524-32. (PMID: 23852814)
      Monogr Soc Res Child Dev. 2013 Aug;78(4):34-48. (PMID: 23952201)
      J Biol. 2008;7(4):11. (PMID: 18439322)
      AJNR Am J Neuroradiol. 2000 Sep;21(8):1397-401. (PMID: 11003270)
      Support Care Cancer. 2014 Aug;22(8):2127-31. (PMID: 24647490)
      Neuroimage. 2007 Mar;35(1):396-405. (PMID: 17239622)
      Breast Cancer Res Treat. 2010 May;121(1):91-100. (PMID: 20306129)
      Curr Oncol Rep. 2013 Jun;15(3):260-9. (PMID: 23483375)
      Psychooncology. 2006 May;15(5):422-30. (PMID: 16097037)
      Br J Haematol. 2016 Sep;174(6):835-46. (PMID: 27391367)
      Eur J Oncol Nurs. 2007 Feb;11(1):6-15. (PMID: 16844416)
      Front Hum Neurosci. 2012 Oct 11;6:281. (PMID: 23087635)
      Eur J Cancer Care (Engl). 2012 Jul;21(4):485-92. (PMID: 22211832)
      Comput Biomed Res. 1996 Jun;29(3):162-73. (PMID: 8812068)
      J Biol. 2006;5(7):22. (PMID: 17125495)
      J Clin Oncol. 2007 Sep 1;25(25):3866-70. (PMID: 17761972)
      Cancer. 2010 Jul 15;116(14):3348-56. (PMID: 20564075)
      Int J Neuropsychopharmacol. 2017 May 1;20(5):374-382. (PMID: 28177081)
      Cancer. 2007 May 1;109(9):1905-13. (PMID: 17351951)
      Neuroimage Clin. 2017 Mar 16;14:685-691. (PMID: 28377882)
      Neuroimage. 1995 Sep;2(3):195-200. (PMID: 9343602)
      Hippocampus. 2015 Sep;25(9):1028-41. (PMID: 25620526)
      Breast Cancer Res Treat. 2013 Apr;138(3):657-64. (PMID: 23532539)
      Neurology. 2012 Jun 5;78(23):1860-7. (PMID: 22573626)
      J Am Geriatr Soc. 2006 Jun;54(6):925-31. (PMID: 16776787)
      Science. 2014 Aug 29;345(6200):1054-7. (PMID: 25170153)
      Cereb Cortex. 2011 Oct;21(10):2272-81. (PMID: 21368086)
      J Neurosci. 2013 Jul 3;33(27):11061-9. (PMID: 23825411)
      Int Rev Neurobiol. 2016;129:1-31. (PMID: 27503446)
      Int Rev Psychiatry. 2014 Feb;26(1):102-13. (PMID: 24716504)
      Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3516-21. (PMID: 22315406)
      Semin Oncol. 2011 Jun;38(3):431-8. (PMID: 21600374)
      Cancer Treat Rev. 2012 Nov;38(7):926-34. (PMID: 22658913)
      Neurology. 2005 Aug 9;65(3):404-11. (PMID: 16087905)
      Neurobiol Dis. 2012 Dec;48(3):329-38. (PMID: 22820143)
    • Grant Information:
      R01 MH106781 United States MH NIMH NIH HHS
    • Accession Number:
      0 (Estrogen Antagonists)
      0 (Inflammation Mediators)
      094ZI81Y45 (Tamoxifen)
    • Publication Date:
      Date Created: 20180811 Date Completed: 20190121 Latest Revision: 20220331
    • Publication Date:
      20231215
    • Accession Number:
      PMC6077172
    • Accession Number:
      10.1016/j.nicl.2018.07.010
    • Accession Number:
      30094161